TW200744670A - Methods for the treatment of macular degeneration and related eye conditions - Google Patents

Methods for the treatment of macular degeneration and related eye conditions

Info

Publication number
TW200744670A
TW200744670A TW096106212A TW96106212A TW200744670A TW 200744670 A TW200744670 A TW 200744670A TW 096106212 A TW096106212 A TW 096106212A TW 96106212 A TW96106212 A TW 96106212A TW 200744670 A TW200744670 A TW 200744670A
Authority
TW
Taiwan
Prior art keywords
macular degeneration
treatment
methods
eye conditions
related eye
Prior art date
Application number
TW096106212A
Other languages
English (en)
Chinese (zh)
Inventor
Milton Lethan Pressler
William Sasiela
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200744670A publication Critical patent/TW200744670A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW096106212A 2006-02-21 2007-02-16 Methods for the treatment of macular degeneration and related eye conditions TW200744670A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77552006P 2006-02-21 2006-02-21

Publications (1)

Publication Number Publication Date
TW200744670A true TW200744670A (en) 2007-12-16

Family

ID=38226652

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096106212A TW200744670A (en) 2006-02-21 2007-02-16 Methods for the treatment of macular degeneration and related eye conditions

Country Status (4)

Country Link
JP (1) JP2007224032A (fr)
AR (1) AR059581A1 (fr)
TW (1) TW200744670A (fr)
WO (1) WO2007096744A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009107753A1 (fr) * 2008-02-29 2009-09-03 財団法人 名古屋産業科学研究所 Liposome pour une administration au segment postérieur de l'œil et composition pharmaceutique pour une maladie du segment postérieur de l'œil
EP3445335A4 (fr) * 2016-04-19 2020-03-04 Nanyang Technological University Formulations formant un dépôt sous-conjonctival pour l'administration de médicament au niveau de l'oeil

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141018A1 (de) * 2001-08-22 2003-03-13 Eth Zuerich Eidgenoessische Te Verwendung von negativ geladenen Phospholipiden, sowie Zusammensetzungen umfassend Phospholipide zur Behandlung des Auges
US20050260260A1 (en) * 2004-05-19 2005-11-24 Edward Kisak Liposome compositions for the delivery of macromolecules
WO2007038549A1 (fr) * 2005-09-26 2007-04-05 Vasogen Ireland Limited Traitement d'inflammations et d'anomalies vasculaires de l'oeil

Also Published As

Publication number Publication date
JP2007224032A (ja) 2007-09-06
AR059581A1 (es) 2008-04-16
WO2007096744A1 (fr) 2007-08-30

Similar Documents

Publication Publication Date Title
WO2007098122A3 (fr) Méthodes pour traiter une dégénérescence maculaire et des troubles apparentés de l'œil
TN2013000275A1 (en) Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
CY1116062T1 (el) Προληπτικη και θεραπευτικη αγωγη οφθαλμικων παθησεων σχετιζομενων με συμπληρωμα
PH12015501207A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
ATE510538T1 (de) Zusammensetzungen und verfahren für nervenschutz
MY155320A (en) Alkoxy compounds for disease treatment
MX2009009738A (es) Tratamiento de degeneracion macular relacionada con la edad usando inhibidores de factor d de complemento.
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
JO3065B1 (ar) مركبات وتركيبات كمعدلات لفاعلية tlr
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
EA201270018A1 (ru) Опсинсвязывающие лиганды, композиции и способы использования
ZA200809493B (en) Method of treatment of age-related macular degeneration (AMD)
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
MX2009009636A (es) Metodos para tratar enfermedades oftalmicas.
MX2010000351A (es) Compuestos derivados de alquinil fenilo para tratar enfermedades y desordenes oftalmicos.
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
WO2010121164A3 (fr) Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
EA201190337A1 (ru) Способ лечения
EA200900582A1 (ru) Фармацевтические композиции для профилактики и лечения глазных патологий
WO2008063808A3 (fr) Nanostructures amphiphiles peptidiques encapsulées
EP1885371A4 (fr) Compositions therapeutiques et methodes associees
IN2014CN03123A (fr)
MY153738A (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders.